nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Erlotinib—pancreatic cancer	0.198	0.325	CbGbCtD
Naltrexone—UGT1A1—Irinotecan—pancreatic cancer	0.179	0.294	CbGbCtD
Naltrexone—ABCB1—Tamoxifen—pancreatic cancer	0.0461	0.0759	CbGbCtD
Naltrexone—ABCB1—Gemcitabine—pancreatic cancer	0.0397	0.0654	CbGbCtD
Naltrexone—ABCB1—Erlotinib—pancreatic cancer	0.0392	0.0645	CbGbCtD
Naltrexone—ABCB1—Irinotecan—pancreatic cancer	0.0354	0.0583	CbGbCtD
Naltrexone—ABCB1—Docetaxel—pancreatic cancer	0.026	0.0427	CbGbCtD
Naltrexone—ABCB1—Sunitinib—pancreatic cancer	0.0258	0.0425	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—pancreatic cancer	0.0194	0.0318	CbGbCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000193	0.000701	CcSEcCtD
Naltrexone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000193	0.0007	CcSEcCtD
Naltrexone—Bronchitis—Epirubicin—pancreatic cancer	0.000192	0.000699	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000192	0.000696	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000189	0.000686	CcSEcCtD
Naltrexone—Vomiting—Sunitinib—pancreatic cancer	0.000188	0.000684	CcSEcCtD
Naltrexone—Body temperature increased—Gemcitabine—pancreatic cancer	0.000188	0.000683	CcSEcCtD
Naltrexone—Rash—Sunitinib—pancreatic cancer	0.000187	0.000679	CcSEcCtD
Naltrexone—Dermatitis—Sunitinib—pancreatic cancer	0.000187	0.000678	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000186	0.000676	CcSEcCtD
Naltrexone—Urticaria—Fluorouracil—pancreatic cancer	0.000186	0.000675	CcSEcCtD
Naltrexone—Headache—Sunitinib—pancreatic cancer	0.000186	0.000674	CcSEcCtD
Naltrexone—Syncope—Docetaxel—pancreatic cancer	0.000185	0.000674	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—pancreatic cancer	0.000185	0.000673	CcSEcCtD
Naltrexone—Body temperature increased—Fluorouracil—pancreatic cancer	0.000185	0.000671	CcSEcCtD
Naltrexone—Palpitations—Docetaxel—pancreatic cancer	0.000183	0.000664	CcSEcCtD
Naltrexone—Weight increased—Epirubicin—pancreatic cancer	0.000182	0.000662	CcSEcCtD
Naltrexone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000182	0.00066	CcSEcCtD
Naltrexone—Weight decreased—Epirubicin—pancreatic cancer	0.000181	0.000658	CcSEcCtD
Naltrexone—Cough—Docetaxel—pancreatic cancer	0.00018	0.000655	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—pancreatic cancer	0.00018	0.000655	CcSEcCtD
Naltrexone—Hypersensitivity—Irinotecan—pancreatic cancer	0.00018	0.000653	CcSEcCtD
Naltrexone—Pneumonia—Epirubicin—pancreatic cancer	0.000179	0.000652	CcSEcCtD
Naltrexone—Convulsion—Docetaxel—pancreatic cancer	0.000179	0.000651	CcSEcCtD
Naltrexone—Hypertension—Docetaxel—pancreatic cancer	0.000178	0.000648	CcSEcCtD
Naltrexone—Infestation NOS—Epirubicin—pancreatic cancer	0.000178	0.000648	CcSEcCtD
Naltrexone—Infestation—Epirubicin—pancreatic cancer	0.000178	0.000648	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—pancreatic cancer	0.000178	0.000647	CcSEcCtD
Naltrexone—Arthralgia—Docetaxel—pancreatic cancer	0.000176	0.000639	CcSEcCtD
Naltrexone—Chest pain—Docetaxel—pancreatic cancer	0.000176	0.000639	CcSEcCtD
Naltrexone—Myalgia—Docetaxel—pancreatic cancer	0.000176	0.000639	CcSEcCtD
Naltrexone—Nausea—Sunitinib—pancreatic cancer	0.000176	0.000639	CcSEcCtD
Naltrexone—Asthenia—Irinotecan—pancreatic cancer	0.000175	0.000636	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000175	0.000635	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—pancreatic cancer	0.000173	0.00063	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—pancreatic cancer	0.000173	0.00063	CcSEcCtD
Naltrexone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000172	0.000626	CcSEcCtD
Naltrexone—Dry mouth—Docetaxel—pancreatic cancer	0.000172	0.000625	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000172	0.000625	CcSEcCtD
Naltrexone—Asthenia—Gemcitabine—pancreatic cancer	0.000171	0.00062	CcSEcCtD
Naltrexone—Confusional state—Docetaxel—pancreatic cancer	0.00017	0.000618	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000169	0.000613	CcSEcCtD
Naltrexone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000169	0.000613	CcSEcCtD
Naltrexone—Oedema—Docetaxel—pancreatic cancer	0.000169	0.000613	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—pancreatic cancer	0.000169	0.000612	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—pancreatic cancer	0.000168	0.000611	CcSEcCtD
Naltrexone—Pruritus—Gemcitabine—pancreatic cancer	0.000168	0.000611	CcSEcCtD
Naltrexone—Infection—Docetaxel—pancreatic cancer	0.000168	0.000609	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—pancreatic cancer	0.000168	0.000609	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—pancreatic cancer	0.000167	0.000608	CcSEcCtD
Naltrexone—Diarrhoea—Irinotecan—pancreatic cancer	0.000167	0.000607	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—pancreatic cancer	0.000166	0.000603	CcSEcCtD
Naltrexone—Shock—Docetaxel—pancreatic cancer	0.000166	0.000603	CcSEcCtD
Naltrexone—Nervous system disorder—Docetaxel—pancreatic cancer	0.000165	0.000601	CcSEcCtD
Naltrexone—Pruritus—Fluorouracil—pancreatic cancer	0.000165	0.000601	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—pancreatic cancer	0.000165	0.0006	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—pancreatic cancer	0.000165	0.0006	CcSEcCtD
Naltrexone—Tachycardia—Docetaxel—pancreatic cancer	0.000165	0.000598	CcSEcCtD
Naltrexone—Skin disorder—Docetaxel—pancreatic cancer	0.000164	0.000595	CcSEcCtD
Naltrexone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000163	0.000591	CcSEcCtD
Naltrexone—Dizziness—Irinotecan—pancreatic cancer	0.000161	0.000586	CcSEcCtD
Naltrexone—Anorexia—Docetaxel—pancreatic cancer	0.000161	0.000584	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00016	0.000583	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—pancreatic cancer	0.00016	0.000583	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—pancreatic cancer	0.00016	0.000582	CcSEcCtD
Naltrexone—Diarrhoea—Fluorouracil—pancreatic cancer	0.00016	0.000581	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—pancreatic cancer	0.000159	0.000578	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000157	0.000572	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000156	0.000567	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—pancreatic cancer	0.000156	0.000566	CcSEcCtD
Naltrexone—Vomiting—Irinotecan—pancreatic cancer	0.000155	0.000564	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—pancreatic cancer	0.000155	0.000563	CcSEcCtD
Naltrexone—Dizziness—Fluorouracil—pancreatic cancer	0.000155	0.000562	CcSEcCtD
Naltrexone—Rash—Irinotecan—pancreatic cancer	0.000154	0.000559	CcSEcCtD
Naltrexone—Dermatitis—Irinotecan—pancreatic cancer	0.000154	0.000559	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000154	0.000558	CcSEcCtD
Naltrexone—Headache—Irinotecan—pancreatic cancer	0.000153	0.000555	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—pancreatic cancer	0.000153	0.000554	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—pancreatic cancer	0.000152	0.00055	CcSEcCtD
Naltrexone—Vomiting—Gemcitabine—pancreatic cancer	0.000151	0.000549	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—pancreatic cancer	0.00015	0.000546	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—pancreatic cancer	0.00015	0.000545	CcSEcCtD
Naltrexone—Rash—Gemcitabine—pancreatic cancer	0.00015	0.000545	CcSEcCtD
Naltrexone—Dermatitis—Gemcitabine—pancreatic cancer	0.00015	0.000544	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—pancreatic cancer	0.00015	0.000544	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—pancreatic cancer	0.000149	0.000543	CcSEcCtD
Naltrexone—Headache—Gemcitabine—pancreatic cancer	0.000149	0.000541	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—pancreatic cancer	0.000149	0.00054	CcSEcCtD
Naltrexone—Vomiting—Fluorouracil—pancreatic cancer	0.000149	0.00054	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—pancreatic cancer	0.000148	0.000538	CcSEcCtD
Naltrexone—Rash—Fluorouracil—pancreatic cancer	0.000147	0.000535	CcSEcCtD
Naltrexone—Dermatitis—Fluorouracil—pancreatic cancer	0.000147	0.000535	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—pancreatic cancer	0.000147	0.000534	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—pancreatic cancer	0.000147	0.000533	CcSEcCtD
Naltrexone—Headache—Fluorouracil—pancreatic cancer	0.000146	0.000532	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000146	0.000529	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000146	0.000529	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—pancreatic cancer	0.000145	0.000528	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—pancreatic cancer	0.000145	0.000528	CcSEcCtD
Naltrexone—Nausea—Irinotecan—pancreatic cancer	0.000145	0.000527	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—pancreatic cancer	0.000145	0.000526	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000144	0.000524	CcSEcCtD
Naltrexone—Pain—Docetaxel—pancreatic cancer	0.000144	0.000524	CcSEcCtD
Naltrexone—Constipation—Docetaxel—pancreatic cancer	0.000144	0.000524	CcSEcCtD
Naltrexone—Chills—Epirubicin—pancreatic cancer	0.000144	0.000522	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—pancreatic cancer	0.000142	0.000514	CcSEcCtD
Naltrexone—Nausea—Gemcitabine—pancreatic cancer	0.000141	0.000513	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—pancreatic cancer	0.00014	0.00051	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—pancreatic cancer	0.000139	0.000507	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000139	0.000505	CcSEcCtD
Naltrexone—Nausea—Fluorouracil—pancreatic cancer	0.000139	0.000504	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—pancreatic cancer	0.000139	0.000503	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—pancreatic cancer	0.000138	0.000502	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000138	0.000501	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000138	0.0005	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—pancreatic cancer	0.000137	0.000499	CcSEcCtD
Naltrexone—Tension—Epirubicin—pancreatic cancer	0.000137	0.000497	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—pancreatic cancer	0.000137	0.000496	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—pancreatic cancer	0.000135	0.000492	CcSEcCtD
Naltrexone—Back pain—Epirubicin—pancreatic cancer	0.000135	0.00049	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—pancreatic cancer	0.000134	0.000489	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—pancreatic cancer	0.000134	0.000487	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—pancreatic cancer	0.000134	0.000486	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000134	0.000485	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—pancreatic cancer	0.000133	0.000485	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—pancreatic cancer	0.000133	0.000485	CcSEcCtD
Naltrexone—Chills—Doxorubicin—pancreatic cancer	0.000133	0.000483	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—pancreatic cancer	0.000131	0.000477	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—pancreatic cancer	0.000131	0.000476	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—pancreatic cancer	0.00013	0.000472	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000129	0.00047	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—pancreatic cancer	0.000129	0.000469	CcSEcCtD
Naltrexone—Agitation—Epirubicin—pancreatic cancer	0.000128	0.000466	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—pancreatic cancer	0.000127	0.000462	CcSEcCtD
Naltrexone—Tension—Doxorubicin—pancreatic cancer	0.000127	0.00046	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000126	0.000459	CcSEcCtD
Naltrexone—Malaise—Epirubicin—pancreatic cancer	0.000126	0.000457	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—pancreatic cancer	0.000125	0.000455	CcSEcCtD
Naltrexone—Syncope—Epirubicin—pancreatic cancer	0.000125	0.000454	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—pancreatic cancer	0.000125	0.000453	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000124	0.000452	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—pancreatic cancer	0.000124	0.000451	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—pancreatic cancer	0.000123	0.000448	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000123	0.000445	CcSEcCtD
Naltrexone—Cough—Epirubicin—pancreatic cancer	0.000122	0.000442	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—pancreatic cancer	0.000122	0.000442	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—pancreatic cancer	0.000121	0.00044	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—pancreatic cancer	0.000121	0.000439	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—pancreatic cancer	0.00012	0.000437	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.00012	0.000435	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—pancreatic cancer	0.000119	0.000434	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—pancreatic cancer	0.000119	0.000431	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—pancreatic cancer	0.000119	0.000431	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—pancreatic cancer	0.000119	0.000431	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—pancreatic cancer	0.000119	0.000431	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—pancreatic cancer	0.000118	0.00043	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000118	0.000428	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—pancreatic cancer	0.000117	0.000426	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—pancreatic cancer	0.000116	0.000423	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—pancreatic cancer	0.000116	0.000422	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—pancreatic cancer	0.000116	0.00042	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—pancreatic cancer	0.000115	0.000419	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—pancreatic cancer	0.000115	0.000417	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—pancreatic cancer	0.000114	0.000414	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000114	0.000413	CcSEcCtD
Naltrexone—Oedema—Epirubicin—pancreatic cancer	0.000114	0.000413	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000113	0.000412	CcSEcCtD
Naltrexone—Infection—Epirubicin—pancreatic cancer	0.000113	0.000411	CcSEcCtD
Naltrexone—Cough—Doxorubicin—pancreatic cancer	0.000113	0.000409	CcSEcCtD
Naltrexone—Shock—Epirubicin—pancreatic cancer	0.000112	0.000407	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—pancreatic cancer	0.000112	0.000406	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—pancreatic cancer	0.000112	0.000405	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—pancreatic cancer	0.000112	0.000405	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—pancreatic cancer	0.000111	0.000405	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—pancreatic cancer	0.000111	0.000403	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—pancreatic cancer	0.000111	0.000402	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00011	0.0004	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—pancreatic cancer	0.00011	0.000399	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—pancreatic cancer	0.00011	0.000399	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—pancreatic cancer	0.00011	0.000399	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—pancreatic cancer	0.000109	0.000398	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000109	0.000396	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—pancreatic cancer	0.000109	0.000394	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—pancreatic cancer	0.000108	0.000394	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—pancreatic cancer	0.000107	0.00039	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—pancreatic cancer	0.000107	0.00039	CcSEcCtD
Naltrexone—Rash—Docetaxel—pancreatic cancer	0.000106	0.000386	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—pancreatic cancer	0.000106	0.000386	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—pancreatic cancer	0.000106	0.000386	CcSEcCtD
Naltrexone—Headache—Docetaxel—pancreatic cancer	0.000106	0.000384	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000105	0.000383	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—pancreatic cancer	0.000105	0.000383	CcSEcCtD
Naltrexone—Infection—Doxorubicin—pancreatic cancer	0.000105	0.00038	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000104	0.000377	CcSEcCtD
Naltrexone—Shock—Doxorubicin—pancreatic cancer	0.000104	0.000376	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000103	0.000375	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—pancreatic cancer	0.000103	0.000374	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—pancreatic cancer	0.000103	0.000373	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—pancreatic cancer	0.000102	0.000372	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—pancreatic cancer	0.000102	0.000371	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000102	0.00037	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—pancreatic cancer	0.000101	0.000369	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—pancreatic cancer	0.000101	0.000368	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—pancreatic cancer	0.0001	0.000365	CcSEcCtD
Naltrexone—Nausea—Docetaxel—pancreatic cancer	0.0001	0.000364	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—pancreatic cancer	9.89e-05	0.000359	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.82e-05	0.000357	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—pancreatic cancer	9.81e-05	0.000356	CcSEcCtD
Naltrexone—Pain—Epirubicin—pancreatic cancer	9.73e-05	0.000354	CcSEcCtD
Naltrexone—Constipation—Epirubicin—pancreatic cancer	9.73e-05	0.000354	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.59e-05	0.000349	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—pancreatic cancer	9.52e-05	0.000346	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—pancreatic cancer	9.46e-05	0.000343	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—pancreatic cancer	9.39e-05	0.000341	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—pancreatic cancer	9.38e-05	0.000341	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—pancreatic cancer	9.36e-05	0.00034	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.31e-05	0.000338	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—pancreatic cancer	9.15e-05	0.000333	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	9.09e-05	0.00033	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—pancreatic cancer	9.08e-05	0.00033	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—pancreatic cancer	9.04e-05	0.000328	CcSEcCtD
Naltrexone—Pain—Doxorubicin—pancreatic cancer	9e-05	0.000327	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—pancreatic cancer	9e-05	0.000327	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—pancreatic cancer	9e-05	0.000327	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—pancreatic cancer	9e-05	0.000327	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—pancreatic cancer	8.68e-05	0.000315	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.61e-05	0.000313	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—pancreatic cancer	8.38e-05	0.000305	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—pancreatic cancer	8.37e-05	0.000304	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—pancreatic cancer	8.32e-05	0.000302	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—pancreatic cancer	8.32e-05	0.000302	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—pancreatic cancer	8.17e-05	0.000297	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—pancreatic cancer	8.05e-05	0.000292	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—pancreatic cancer	7.79e-05	0.000283	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—pancreatic cancer	7.76e-05	0.000282	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—pancreatic cancer	7.55e-05	0.000274	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—pancreatic cancer	7.53e-05	0.000273	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—pancreatic cancer	7.45e-05	0.000271	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—pancreatic cancer	7.24e-05	0.000263	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—pancreatic cancer	7.2e-05	0.000262	CcSEcCtD
Naltrexone—Rash—Epirubicin—pancreatic cancer	7.18e-05	0.000261	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—pancreatic cancer	7.17e-05	0.00026	CcSEcCtD
Naltrexone—Headache—Epirubicin—pancreatic cancer	7.13e-05	0.000259	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—pancreatic cancer	6.96e-05	0.000253	CcSEcCtD
Naltrexone—Nausea—Epirubicin—pancreatic cancer	6.76e-05	0.000246	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—pancreatic cancer	6.7e-05	0.000243	CcSEcCtD
Naltrexone—Rash—Doxorubicin—pancreatic cancer	6.64e-05	0.000241	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—pancreatic cancer	6.63e-05	0.000241	CcSEcCtD
Naltrexone—Headache—Doxorubicin—pancreatic cancer	6.6e-05	0.00024	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—pancreatic cancer	6.25e-05	0.000227	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—CCK—pancreatic cancer	6.24e-05	0.000535	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SHH—pancreatic cancer	6.22e-05	0.000533	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRP1—pancreatic cancer	6.2e-05	0.000532	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PPP2R5B—pancreatic cancer	6.2e-05	0.000532	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—DPYD—pancreatic cancer	6.18e-05	0.00053	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH4—pancreatic cancer	6.18e-05	0.00053	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IAPP—pancreatic cancer	6.14e-05	0.000527	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CNR2—pancreatic cancer	6.08e-05	0.000521	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GLP1R—pancreatic cancer	6.08e-05	0.000521	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL8—pancreatic cancer	6.08e-05	0.000521	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GCG—pancreatic cancer	6.03e-05	0.000517	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCKAR—pancreatic cancer	5.98e-05	0.000513	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HEY2—pancreatic cancer	5.97e-05	0.000512	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTHLH—pancreatic cancer	5.9e-05	0.000506	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTCH1—pancreatic cancer	5.9e-05	0.000506	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC2A2—pancreatic cancer	5.87e-05	0.000503	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GAST—pancreatic cancer	5.83e-05	0.0005	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAG2—pancreatic cancer	5.8e-05	0.000497	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGTR1—pancreatic cancer	5.75e-05	0.000493	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	5.75e-05	0.000493	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MEN1—pancreatic cancer	5.72e-05	0.00049	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	5.7e-05	0.000488	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SCT—pancreatic cancer	5.53e-05	0.000474	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HEY1—pancreatic cancer	5.53e-05	0.000474	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SHH—pancreatic cancer	5.45e-05	0.000468	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH4—pancreatic cancer	5.42e-05	0.000465	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SST—pancreatic cancer	5.39e-05	0.000462	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IAPP—pancreatic cancer	5.39e-05	0.000462	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.32e-05	0.000456	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JAG1—pancreatic cancer	5.28e-05	0.000453	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCK—pancreatic cancer	5.27e-05	0.000452	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH3—pancreatic cancer	5.26e-05	0.000451	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTHLH—pancreatic cancer	5.17e-05	0.000443	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTCH1—pancreatic cancer	5.17e-05	0.000443	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GLP1R—pancreatic cancer	5.14e-05	0.000441	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CNR2—pancreatic cancer	5.14e-05	0.000441	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—pancreatic cancer	5.14e-05	0.00044	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCKAR—pancreatic cancer	5.06e-05	0.000434	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CNR1—pancreatic cancer	4.98e-05	0.000427	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAG2—pancreatic cancer	4.9e-05	0.00042	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	4.84e-05	0.000415	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MEN1—pancreatic cancer	4.83e-05	0.000414	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CG—pancreatic cancer	4.83e-05	0.000414	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GCG—pancreatic cancer	4.81e-05	0.000412	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SST—pancreatic cancer	4.73e-05	0.000406	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PRSS1—pancreatic cancer	4.72e-05	0.000405	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CD—pancreatic cancer	4.68e-05	0.000401	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CG—pancreatic cancer	4.66e-05	0.0004	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAG1—pancreatic cancer	4.63e-05	0.000397	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SHH—pancreatic cancer	4.61e-05	0.000395	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH3—pancreatic cancer	4.61e-05	0.000395	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGTR1—pancreatic cancer	4.59e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH4—pancreatic cancer	4.58e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IAPP—pancreatic cancer	4.55e-05	0.00039	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CD44—pancreatic cancer	4.54e-05	0.00039	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STK11—pancreatic cancer	4.52e-05	0.000388	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	4.5e-05	0.000386	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	4.38e-05	0.000375	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTCH1—pancreatic cancer	4.37e-05	0.000375	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTHLH—pancreatic cancer	4.37e-05	0.000375	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CNR1—pancreatic cancer	4.36e-05	0.000374	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GCG—pancreatic cancer	4.36e-05	0.000374	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	4.33e-05	0.000372	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CD—pancreatic cancer	4.25e-05	0.000364	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CG—pancreatic cancer	4.24e-05	0.000363	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	4.22e-05	0.000362	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GCG—pancreatic cancer	4.22e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CD—pancreatic cancer	4.1e-05	0.000352	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—STK11—pancreatic cancer	4.1e-05	0.000351	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ARG2—pancreatic cancer	4.09e-05	0.000351	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.08e-05	0.000349	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGTR1—pancreatic cancer	4.02e-05	0.000345	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SST—pancreatic cancer	4e-05	0.000343	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STK11—pancreatic cancer	3.96e-05	0.00034	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SMAD4—pancreatic cancer	3.96e-05	0.000339	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CG—pancreatic cancer	3.94e-05	0.000338	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	3.92e-05	0.000336	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—pancreatic cancer	3.92e-05	0.000336	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAG1—pancreatic cancer	3.91e-05	0.000335	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH3—pancreatic cancer	3.9e-05	0.000334	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HES1—pancreatic cancer	3.87e-05	0.000331	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	3.82e-05	0.000327	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CD—pancreatic cancer	3.72e-05	0.000319	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CB—pancreatic cancer	3.7e-05	0.000317	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CNR1—pancreatic cancer	3.69e-05	0.000316	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	3.58e-05	0.000307	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMP—pancreatic cancer	3.58e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.57e-05	0.000306	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GCG—pancreatic cancer	3.56e-05	0.000305	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—pancreatic cancer	3.56e-05	0.000305	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMS—pancreatic cancer	3.52e-05	0.000302	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	3.51e-05	0.000301	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	3.5e-05	0.0003	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SMAD4—pancreatic cancer	3.47e-05	0.000298	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.47e-05	0.000297	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—pancreatic cancer	3.43e-05	0.000294	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	3.43e-05	0.000294	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGTR1—pancreatic cancer	3.4e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HES1—pancreatic cancer	3.39e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TERT—pancreatic cancer	3.39e-05	0.00029	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STK11—pancreatic cancer	3.35e-05	0.000287	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	3.27e-05	0.00028	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CB—pancreatic cancer	3.25e-05	0.000278	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	3.24e-05	0.000278	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—pancreatic cancer	3.24e-05	0.000278	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TSC2—pancreatic cancer	3.23e-05	0.000277	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—pancreatic cancer	3.16e-05	0.000271	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	3.15e-05	0.00027	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—pancreatic cancer	3.12e-05	0.000267	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—pancreatic cancer	3.1e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.02e-05	0.000259	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	2.98e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—pancreatic cancer	2.97e-05	0.000255	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKBIA—pancreatic cancer	2.95e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SMAD4—pancreatic cancer	2.93e-05	0.000252	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—pancreatic cancer	2.92e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	2.9e-05	0.000249	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GLP1R—pancreatic cancer	2.88e-05	0.000247	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	2.88e-05	0.000247	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—pancreatic cancer	2.87e-05	0.000246	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HES1—pancreatic cancer	2.86e-05	0.000246	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—pancreatic cancer	2.85e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—NRAS—pancreatic cancer	2.85e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—pancreatic cancer	2.84e-05	0.000244	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DPYD—pancreatic cancer	2.84e-05	0.000243	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC2—pancreatic cancer	2.83e-05	0.000243	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGF—pancreatic cancer	2.82e-05	0.000242	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—pancreatic cancer	2.77e-05	0.000238	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	2.74e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—pancreatic cancer	2.72e-05	0.000233	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A2—pancreatic cancer	2.69e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—pancreatic cancer	2.64e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—pancreatic cancer	2.6e-05	0.000223	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—pancreatic cancer	2.59e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKBIA—pancreatic cancer	2.58e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—pancreatic cancer	2.56e-05	0.000219	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—pancreatic cancer	2.51e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—pancreatic cancer	2.51e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—pancreatic cancer	2.5e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—NRAS—pancreatic cancer	2.5e-05	0.000215	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—pancreatic cancer	2.5e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.48e-05	0.000213	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGF—pancreatic cancer	2.47e-05	0.000212	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—pancreatic cancer	2.46e-05	0.000211	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.43e-05	0.000209	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—pancreatic cancer	2.4e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC2—pancreatic cancer	2.39e-05	0.000205	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—pancreatic cancer	2.34e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—pancreatic cancer	2.3e-05	0.000197	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—pancreatic cancer	2.28e-05	0.000195	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—pancreatic cancer	2.27e-05	0.000195	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.26e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—pancreatic cancer	2.2e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—pancreatic cancer	2.19e-05	0.000187	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKBIA—pancreatic cancer	2.18e-05	0.000187	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.18e-05	0.000187	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—pancreatic cancer	2.16e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—pancreatic cancer	2.15e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—pancreatic cancer	2.11e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—NRAS—pancreatic cancer	2.11e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—pancreatic cancer	2.1e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGF—pancreatic cancer	2.09e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—pancreatic cancer	2.09e-05	0.000179	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD44—pancreatic cancer	2.08e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—pancreatic cancer	2.03e-05	0.000174	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—pancreatic cancer	2.01e-05	0.000172	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCG—pancreatic cancer	2e-05	0.000171	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—pancreatic cancer	1.98e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.98e-05	0.00017	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—pancreatic cancer	1.96e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—pancreatic cancer	1.96e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNB1—pancreatic cancer	1.94e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—pancreatic cancer	1.93e-05	0.000165	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—pancreatic cancer	1.92e-05	0.000164	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—pancreatic cancer	1.9e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—pancreatic cancer	1.89e-05	0.000162	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—STK11—pancreatic cancer	1.88e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—pancreatic cancer	1.86e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—pancreatic cancer	1.84e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—pancreatic cancer	1.84e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.84e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—pancreatic cancer	1.83e-05	0.000157	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—pancreatic cancer	1.82e-05	0.000156	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—pancreatic cancer	1.78e-05	0.000153	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—pancreatic cancer	1.76e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—pancreatic cancer	1.75e-05	0.00015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—pancreatic cancer	1.72e-05	0.000147	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—pancreatic cancer	1.71e-05	0.000147	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—pancreatic cancer	1.71e-05	0.000146	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNB1—pancreatic cancer	1.7e-05	0.000146	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—pancreatic cancer	1.69e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NRAS—pancreatic cancer	1.69e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.67e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—pancreatic cancer	1.67e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—pancreatic cancer	1.66e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—pancreatic cancer	1.62e-05	0.000139	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—pancreatic cancer	1.62e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—pancreatic cancer	1.62e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—pancreatic cancer	1.57e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—pancreatic cancer	1.57e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—pancreatic cancer	1.56e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—pancreatic cancer	1.55e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—pancreatic cancer	1.54e-05	0.000132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—pancreatic cancer	1.54e-05	0.000132	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—pancreatic cancer	1.5e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—pancreatic cancer	1.5e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—pancreatic cancer	1.49e-05	0.000128	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—pancreatic cancer	1.48e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NRAS—pancreatic cancer	1.48e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—pancreatic cancer	1.45e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—pancreatic cancer	1.45e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNB1—pancreatic cancer	1.44e-05	0.000123	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—pancreatic cancer	1.41e-05	0.000121	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—pancreatic cancer	1.4e-05	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—pancreatic cancer	1.38e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—pancreatic cancer	1.37e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—pancreatic cancer	1.37e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—pancreatic cancer	1.35e-05	0.000115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.33e-05	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—pancreatic cancer	1.31e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—pancreatic cancer	1.3e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—pancreatic cancer	1.29e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—pancreatic cancer	1.27e-05	0.000109	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—pancreatic cancer	1.26e-05	0.000108	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—pancreatic cancer	1.25e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRAS—pancreatic cancer	1.25e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—pancreatic cancer	1.23e-05	0.000106	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	1.21e-05	0.000104	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.19e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—pancreatic cancer	1.17e-05	0.0001	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—pancreatic cancer	1.16e-05	9.98e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—pancreatic cancer	1.16e-05	9.95e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—pancreatic cancer	1.15e-05	9.82e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—pancreatic cancer	1.14e-05	9.76e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—pancreatic cancer	1.13e-05	9.7e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—pancreatic cancer	1.09e-05	9.34e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—pancreatic cancer	1.08e-05	9.27e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—pancreatic cancer	1.08e-05	9.22e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.04e-05	8.94e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—pancreatic cancer	9.88e-06	8.47e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—pancreatic cancer	9.87e-06	8.46e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—pancreatic cancer	9.56e-06	8.19e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—pancreatic cancer	9.55e-06	8.19e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—pancreatic cancer	9.14e-06	7.84e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—pancreatic cancer	9.09e-06	7.8e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—pancreatic cancer	9.01e-06	7.72e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—pancreatic cancer	8.07e-06	6.92e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—pancreatic cancer	7.86e-06	6.74e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—pancreatic cancer	5.54e-06	4.75e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—pancreatic cancer	4.53e-06	3.88e-05	CbGpPWpGaD
